HIF-1α Levels in patients receiving chemoradiotherapy for locally advanced non-small cell lung carcinoma

SUMMARY AIM To examine the relationship between treatment response and hypoxia-inducible factor-1 alpha (HIF-1 α ) levels in patients with locally advanced non-small cell lung cancer (NSCLC) who received chemoradiotherapy (CRT). METHODS Eighty patients with NSCLC were included in the study and treated at Acibadem Mehmet Ali Ayd ı nlar University Medical Faculty. HIF-1 α levels were measured before and after CRT by the enzyme-linked immunosorbent assay (ELISA) method. RESULTS Patients ’ stages were as follows; stage IIIA (65%) and stage IIIB (35%). Squamous histology was 45%, adenocarcinoma was 44%, and others were 11%. Chemotherapy and radiotherapy were given concurrently to 80 patients. Forty-five (56%) patients received cisplatin-based chemotherapy, and 35 (44%) received carboplatin-based chemotherapy. Serum HIF-1 α levels (42.90 ± 10.55 pg/mL) after CRT were significantly lower than the pretreatment levels (63.10 ± 10.22 pg/mL, p
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research

Related Links:

Conclusions: EGFR mutated in 10%, mostly in women and non-smokers, all of them adenocarcinoma. Low prevalence of the other mutations. Mutation of EGFR has better prognosis. In the multivariate analysis, the IVA vs IVB stage, ECOG, RT and treatment with ITK in mutated EGFR leads to a better prognosis.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Conclusion: Bronchoscopic re-biopsy for progressive lung cancer is feasible and safe. Histological change can be detected in a considerable number of patients, which is potentially valuable information for guidance of subsequent treatment.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Background: Atezolizumab (anti-PD-L1 antibody) can be used with anti-PD-1 antibodies (nivolumab and pembrolizumab) for treating NSCLC. The safety and efficacy of atezolizumab are unclear in patients who were previously treated with anti-PD-1 antibodies.Aim: To investigate the efficacy and safety of atezolizumab in patients who previously received anti-PD-1 antibodies.Methods: We retrospectively reviewed NSCLC patients who received atezolizumab after receiving anti-PD-1 antibodies. We evaluated tumour PD-L1 expression, cycles of anti-PD-1/PD-L1 antibodies, best response, progression free survival, and prior chemotherapies.R...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Conclusions: IPF is a risk factor for lung cancer development. Squamous cell carcinoma is the most common histologic subtype in patients with IPF. Large randomized controlled studies on the management of patients with IPF and lung cancer are sorely needed.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Idiopathic interstitial pneumonias Source Type: research
Expression of DR5 and c‑FLIP proteins as novel prognostic biomarkers for non‑small cell lung cancer patients treated with surgical resection and chemotherapy. Oncol Rep. 2019 Oct 04;: Authors: Zheng H, Zhang Y, Zhan Y, Liu S, Lu J, Wen Q, Fan S Abstract TRAIL‑R2 (DR5), one of the death receptors, can activate the extrinsic apoptosis pathway, while cellular FLICE‑inhibitory protein (c‑FLIP) can inhibit this pathway. Both of them play important roles in the occurrence and development of most tumors. To date, there is no relevant report concerning the relationship between expression of DR5 and c...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, whom received apatinib (250mg or 500mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second- or more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response rate (ORR), disease control rat...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
ConclusionsThis is the first prospective phase II trial of weekly nabPTX in combination with CBDCA in advanced NSCLC patients with ILD. This treatment showed favorable efficacy and was well tolerated.Clinical trial identificationUMIN000012901.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureT. Harada: Honoraria (institution): GlaxoSmithKline K.K.; Honoraria (institution): Hisamitsu Pharmaceutical Co.,Inc; Honoraria (institution): Boehrnger INgelheim. S. Oizumi: Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Chugai Pharmace...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundTumor Treating Fields (TTFields) are a non-invasive, antimitotic therapy delivered to the tumor via transducer arrays applied to the skin at tumor site. The only TTFields-related adverse event (AE) reported in clinical trials was localized dermatitis beneath the arrays. The safety of TTFields has also been investigated in glioblastoma, non-small-cell lung cancer (NSCLC), mesothelioma, pancreatic and ovarian cancer. This meta-analysis reported AEs in clinical studies with TTFields torso delivery.Methods192 patients from 4 pilot studies were included in the analysis: EF-15 (n  = 41, advanced N...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Abstract PURPOSE: Activation of NFE2L2 has been linked to chemoresistance in cell line models. Recently, somatic mutations which activate NFE2L2, including mutations in NFE2L2,KEAP1, or CUL3,have been found to be associated with poor outcomes in patients with non-small cell lung cancer (NSCLC). However, the impact of these mutations on chemoresistance remains incompletely explored. EXPERIMENTAL DESIGN: We investigated the effect of Keap1 deletion on chemoresistance in cell lines from Trp53-based mouse models of lung squamous cell carcinoma (LSCC) and lung adenocarcinoma (LUAD). Separately, we identified 51 st...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
iğit İ, Savaş İ, Tatar D, Arslan S, Kömürcüoğlu B, Bayram M, Gülmez İ, Doğan ÖT, Özgün Niksarlıoğlu EY, Kaba E, Karaoğlanoğlu S, Aydın Özgür E, Özçelik AE, Özlü T, REDIGMA Study Group Abstract Introduction: The results of standard chemotherapy in lung cancer are not very satisfactory, so it is important to identify genetic mutations that provide targeted therapies. Recent reports have suggested influences of racial difference on the frequency of mutation in lung cancer. We aimed to determine the frequency and regional distribution of ge...
Source: Tuberkuloz ve Toraks - Category: Respiratory Medicine Authors: Tags: Tuberk Toraks Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | General Medicine | Lung Cancer | Men | Non-Small Cell Lung Cancer | Study